Format

Send to

Choose Destination
See comment in PubMed Commons below
Ophthalmology. 2005 Jan;112(1):84-91.

One-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia.

Author information

1
Singapore Eye Research Institute and Singapore National Eye Centre, Singapore. snecdt@pacific.net.sg <snecdt@pacific.net.sg>

Abstract

OBJECTIVE:

To evaluate the safety and efficacy of the relatively selective M(1)-antagonist, pirenzepine ophthalmic gel (gel), in slowing the progression of myopia in school-aged children.

DESIGN:

Parallel-group, placebo-controlled, randomized, double-masked study.

PARTICIPANTS:

Three hundred fifty-three healthy children, 6 to 12 years old, with a spherical equivalent (SE) of -0.75 to -4.00 diopters (D) and astigmatism of <or=1.00 D. Subjects underwent a baseline complete eye examination, and regular examinations over a 1-year period. The study was conducted at 7 academic centers and clinical practices in Asia.

INTERVENTION:

Subjects received 2% gel twice daily (gel/gel), 2% gel daily (evening, placebo/gel), or vehicle twice daily (placebo/placebo) in a 2:2:1 ratio, respectively, for 1 year.

MAIN OUTCOME MEASURE:

Spherical equivalent under cycloplegic refraction.

RESULTS:

At study entry, mean SE refraction was -2.4+/-0.9 D. At 12 months, there was a mean increase in myopia of 0.47 D, 0.70 D, and 0.84 D in the gel/gel, placebo/gel, and placebo/placebo groups, respectively (P<0.001 for gel/gel vs. placebo/placebo). Discontinued from the study for adverse events were 11% (31/282) of pirenzepine-treated subjects. Of the 15 serious adverse events reported in 12 subjects (all in the active groups), none was ophthalmic in nature, all subjects recovered, and only 1 (abdominal colic preceded by a flu) was judged possibly related to treatment.

CONCLUSIONS:

Gel (2% twice daily) was effective and relatively safe in slowing the progression of myopia over a 1-year treatment period.

PMID:
15629825
DOI:
10.1016/j.ophtha.2004.06.038
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center